BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Araki N, Tsuruoka S, Wang N, Hasegawa G, Yanagihara H, Ando H, Omasa T, Enosawa S, Nagai H, Fujimura A. Human CYP3A4-introduced HepG2 cells: In vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity. Xenobiotica 2008;38:1355-64. [DOI: 10.1080/00498250802468645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Cao X, Song Y, Kai J, Yang X, Ji P. Evaluation of EROD and CYP3A4 activities in earthworm Eisenia fetida as biomarkers for soil heavy metal contamination. Journal of Hazardous Materials 2012;243:146-51. [DOI: 10.1016/j.jhazmat.2012.10.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
2 Gómez-Lechón MJ, Tolosa L, Donato MT. Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing. Expert Opin Drug Metab Toxicol 2017;13:137-48. [PMID: 27671376 DOI: 10.1080/17425255.2017.1238459] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
3 Araki N, Tsuruoka S, Hasegawa G, Yanagihara H, Omasa T, Enosawa S, Yamazoe Y, Fujimura A. Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. J Pharm Pharmacol 2012;64:1715-21. [PMID: 23146034 DOI: 10.1111/j.2042-7158.2012.01562.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]